Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
StemProtein is a private biotechnology and pharmaceutical manufacturing company focused on stem cell-derived bioactive products and transdermal delivery technologies. The company manufactures stem cell factors from ischemia-tolerant mesenchymal stem cells, including signaling proteins, growth factors, polysaccharides, and membrane-enclosed vesicles carrying RNA involved in gene regulation. Its products are designed to be heat-stable at room temperature using a proprietary preservation technology, supporting pharmaceutical and aesthetic applications. StemProtein has also developed a patented biodegradable microneedle patch platform for dermal delivery of proteins and other large molecules. The company operates as a subsidiary of Stemedica Cell Technologies and appears to be positioned around enabling and productizing stem cell-derived protein and vesicle formulations rather than running a broad clinical drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on StemProtein.